Company Overview and News
Univar Inc. said Monday that it planned to acquire Nexeo Solutions Inc. for $2 billion in cash and stock, valuing the company at $11.65 a share. Nexeo shares closed at $10.01, and were halted early in the after-hours session ahead of the announcement. Nexeo, which distributes chemicals and plastics, was previously acquired for about $1.6 billion in 2016 by a company run by Wilbur Ross, who has since become the U.
NXEOW ADAP UNVR SBLKL FNFV KHC NXEO BIP NXEOU SBLK FNF
In recent months, two 150-tonne survival bunkers journeyed by land and sea from a Texas warehouse to the shores of New Zealand, where they're buried 11 feet underground.
Fidelity National Financial, Inc. (FNF - Free Report) has announced the pricing of $450 million aggregate principal amount of Senior Notes. The notes carry an interest rate of 4.50% with maturity scheduled on Aug 15, 2028. Following the release of this news, the company gained 0.3% in the last trading session. The company priced the senior notes at 99.252%, which will yield 4.594% on maturity. These notes will pay interest on a semi-annual basis – on February and August, 2019.
FOX STC FNFV PGR LMHA NMIH LMHB FOXA Y FNF LM
Affiliated Managers Group, Inc. (AMG - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $147.23 to $152.43 in the past one month time frame.
CWH MGR FNFV AMG FNF
Net cash and the value of that asset alone support nearly the entire current market cap, leaving a restaurant business, a medical software provider, and assets seemingly for free.
FNFV CNNE FNF RT
MGIC Investment Corporation (MTG - Free Report) reported second-quarter 2018 operating net income per share of 49 cents, surpassing the Zacks Consensus Estimate by 36.1%. The bottom line also soared 58.1% year over year on higher revenues, lower loss and reduction in tax.
FNFV PGR MTG RLI FNF
Fidelity National Financial, Inc.’s (FNF - Free Report) second-quarter 2018 adjusted earnings from continuing operations of 86 cents per share beat the Zacks Consensus Estimate by 3.6%. The bottom line also improved 34.4% year over year.
GEC GE FNFV RE PGR FAF GNE FNF
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM DOV.WI NOV TEL CVS FNF BAC CHTR APY.WI FNFV DOV GM ORCL LBRDB BAC C AAL BHGE COMM MA ARNC TWC LBRDK BHI CGBBW OCLCF JLL LBRDA FL APY UNH
Fidelity National Financial (FNF) is the largest title insurer in the United States. There are several reasons why I think title insurers are a great way to participate in home price appreciation over the next decade. First, banks require title insurance for mortgage transactions, so customers are essentially captive. Second, due to price regulations and a consolidated industry, there is very little price competition.
STC TRV FNFV MET FAF BKI FNF
Thank you for standing by and welcome to the FNF 2018 First Quarter Earnings Call. All participants are in a listen-only mode. Later, there'll be an opportunity for questions. As a reminder, this call is being recorded and will be available for replay after 3:30 PM today through May 10. You may access the replay by dialing 1-800-475-6701 or 320-365-3844 and enter access code 447137.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET